Literature DB >> 12391251

Down-regulation of intestinal lymphocyte activation and Th1 cytokine production by antibiotic therapy in a murine model of Crohn's disease.

Giorgos Bamias1, Marco Marini, Christopher A Moskaluk, Masaru Odashima, William G Ross, Jesús Rivera-Nieves, Fabio Cominelli.   

Abstract

Resident intestinal bacteria likely play an important role in the pathogenesis of Crohn's disease through their interaction with the gut immune system. SAMP1/YitFc mice spontaneously develop chronic, discontinuous, transmural ileitis with many features similar to Crohn's disease. The aim of this study was to determine the effects and elucidate the mechanisms of action of antibiotic treatment in the SAMP1/YitFc mouse model of ileitis. Mice were treated orally with ciprofloxacin and metronidazole before the development of ileitis (prevention protocol) or after ileitis was fully established (treatment protocol). Terminal ilea were harvested for histological scoring, and lamina propria and mesenteric lymph node cells were isolated for analysis of activation markers and cytokine production. Antibiotic therapy significantly decreased the severity of ileitis both in the prevention (40% reduction, p < 0.05) and the treatment (25% reduction, p < 0.01) protocols, compared with untreated, control mice. These effects were associated with a decreased percentage of CD4(+)/CD45RB(high) lymphocytes in mesenteric lymph nodes of antibiotic-treated mice, as well as decreased production of IFN-gamma (prevention: 0.53 +/- 0.21 vs 1.84 +/- 0.04 ng/ml, p < 0.05; treatment: 8.4 +/- 0.4 vs 12.4 +/- 0.7 ng/ml, p < 0.005) and TNF (prevention: 61.5 +/- 13 vs 134 +/- 19 pg/ml, p < 0.01; treatment: 333.5 +/- 11 vs 496 +/- 20 pg/ml, p < 0.001). The number of activated lamina propria lymphocytes was also reduced after antibiotic treatment. In conclusion, antibiotic therapy significantly ameliorates the severity of ileitis in SAMP1/YitFc mice by a mechanism involving down-regulation of activated gut lymphocytes and inhibition of intestinal Th1 cytokine production.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12391251     DOI: 10.4049/jimmunol.169.9.5308

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  27 in total

1.  Bifidobacterium lactis attenuates onset of inflammation in a murine model of colitis.

Authors:  David Philippe; Laurent Favre; Francis Foata; Oskar Adolfsson; Genevieve Perruisseau-Carrier; Karine Vidal; Gloria Reuteler; Johanna Dayer-Schneider; Christoph Mueller; Stéphanie Blum
Journal:  World J Gastroenterol       Date:  2011-01-28       Impact factor: 5.742

Review 2.  Cytokine Networks and T-Cell Subsets in Inflammatory Bowel Diseases.

Authors:  Mei Lan Chen; Mark S Sundrud
Journal:  Inflamm Bowel Dis       Date:  2016-05       Impact factor: 5.325

Review 3.  A possible link between Crohn's disease and ankylosing spondylitis via Klebsiella infections.

Authors:  Alan Ebringer; Taha Rashid; Harmale Tiwana; Clyde Wilson
Journal:  Clin Rheumatol       Date:  2006-08-29       Impact factor: 2.980

Review 4.  Pathway-based approaches to the treatment of inflammatory bowel disease.

Authors:  Giorgos Bamias; Theresa T Pizarro; Fabio Cominelli
Journal:  Transl Res       Date:  2015-09-07       Impact factor: 7.012

Review 5.  Layers of mutualism with commensal bacteria protect us from intestinal inflammation.

Authors:  C Mueller; A J Macpherson
Journal:  Gut       Date:  2006-02       Impact factor: 23.059

Review 6.  Antibiotics and probiotics in treatment of inflammatory bowel disease.

Authors:  Paolo Gionchetti; Fernando Rizzello; Karen-M Lammers; Claudia Morselli; Lucia Sollazzi; Samuel Davies; Rosy Tambasco; Carlo Calabrese; Massimo Campieri
Journal:  World J Gastroenterol       Date:  2006-06-07       Impact factor: 5.742

7.  Probiotics for Crohn's disease: what have we learned?

Authors:  C Prantera
Journal:  Gut       Date:  2006-06       Impact factor: 23.059

Review 8.  Update on the management of Crohn's disease.

Authors:  Anna M Buchner; Wojciech Blonski; Gary R Lichtenstein
Journal:  Curr Gastroenterol Rep       Date:  2011-10

9.  Effect of ciprofloxacin-induced prostaglandin E2 on interleukin-18-treated monocytes.

Authors:  Hideo Kohka Takahashi; Hiromi Iwagaki; Dong Xue; Goutarou Katsuno; Sachi Sugita; Kenji Mizuno; Shuji Mori; Shinya Saito; Tadashi Yoshino; Noriaki Tanaka; Masahiro Nishibori
Journal:  Antimicrob Agents Chemother       Date:  2005-08       Impact factor: 5.191

10.  Absence of bacterially induced RELMbeta reduces injury in the dextran sodium sulfate model of colitis.

Authors:  Laila D McVay; Sue A Keilbaugh; Tracie M H Wong; Sonja Kierstein; Marcus E Shin; Michael Lehrke; Martina I Lefterova; D Edward Shifflett; Sean L Barnes; Fabio Cominelli; Steven M Cohn; Gail Hecht; Mitchell A Lazar; Angela Haczku; Gary D Wu
Journal:  J Clin Invest       Date:  2006-10-05       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.